| Abstrakt: |
A study conducted at the Clinical Hospital Center in Rijeka, Croatia, aimed to evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in cancer patients aged 70 and older. The researchers performed a retrospective chart review of 145 patients and found that the median progression-free survival (PFS) was 10.4 months, with no significant differences between patients in their seventies and eighties. Female gender and first-line treatment setting were associated with a longer median PFS. The study concluded that the effectiveness of ICIs in older cancer patients depends on the line of treatment and treatment discontinuation, and that octogenarians experienced similar treatment responses and adverse effects compared to septuagenarians. [Extracted from the article] |
